The short version of TB-500 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
== Financing and valuation == StoreDot raised over 6 million dollars in an initial investment round, and by the end of 2014 had raised another 42 million dollars. It raised another 62 million dollars by the end of 2017. The company was in negotiations in March 2021 for a SPAC merger at a $3.5 billion valuation. A further funding round of 70-80 million dollars in 2022 gave it a $1.5 billion valuation. The company plans as of 2023 to raise further capital in 2024 or 2025 in order to build up its silicon nanoparticles supply chain and secure dedicated manufacturing capacity for its batteries from existing manufacturers. StoreDot signed a SPAC merger in 2025 at a valuation of $800M. The merger was cancelled in 2026 after the company could not secure $30M in cash for its operations. Financial journalists estimated in February 2026 that StoreDot has funding for a few more months of operations.
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system. In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. By 2012, Kurt Graves had replaced Karling Leung as President and CEO. Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012. As of 2016, Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System, "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides". The drug was rejected for FDA approval in 2017 and 2020.
Molybdenum at The Periodic Table of Videos (University of Nottingham) Mineral & Exploration – Map of World Molybdenum Producers 2009 "Mining A Mountain" Popular Mechanics, July 1935 pp. 63–64 Site for global molybdenum info CDC – NIOSH Pocket Guide to Chemical Hazards usgs.gov: Molybdenum (Mineral Commodity Summaries 2025)
Sources: en.wikipedia.org
== Adrenomedullary hormones == Adrenomedullary hormones are catecholamines secreted from the adrenal medulla by chromaffin cells, neurosecretory cells connected to the central nervous system. The synthesis, storage (in chromaffin cells) and release of catecholamines is co-regulated by synaptic input from their respective pre-synaptic sympathetic neurons, as well as hormonal and local inputs. The adrenomedullary hormones are:
USDA RDA chart in PDF format Archived 9 November 2021 at the Wayback Machine Health Canada Dietary Reference Intakes Reference Chart for Vitamins NIH Office of Dietary Supplements: Fact Sheets Archived 16 September 2008 at the Wayback Machine "Vitamins and minerals". nhs.uk. 23 October 2017.
(S)-corytuberine synthase is an enzyme purified from the plant Coptis japonica (Japanese goldthread), with EC number EC 1.14.19.51 and CYP Symbol CYP80G2. It catalyses an intramolecular C-C phenol coupling of (S)-reticuline to (S)-corytuberine in a pathway leading to magnoflorine.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.